CA3218849A1 - Variants of sirt6 for use in preventing and/or treating age-related diseases - Google Patents

Variants of sirt6 for use in preventing and/or treating age-related diseases Download PDF

Info

Publication number
CA3218849A1
CA3218849A1 CA3218849A CA3218849A CA3218849A1 CA 3218849 A1 CA3218849 A1 CA 3218849A1 CA 3218849 A CA3218849 A CA 3218849A CA 3218849 A CA3218849 A CA 3218849A CA 3218849 A1 CA3218849 A1 CA 3218849A1
Authority
CA
Canada
Prior art keywords
sirt6
vector
nucleic acid
acid molecule
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3218849A
Other languages
English (en)
French (fr)
Inventor
Vera Gorbunova
Andrei Seluanov
Yousin SUH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Albert Einstein College of Medicine
University of Rochester
Original Assignee
Columbia University in the City of New York
Albert Einstein College of Medicine
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York, Albert Einstein College of Medicine, University of Rochester filed Critical Columbia University in the City of New York
Publication of CA3218849A1 publication Critical patent/CA3218849A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02K—DYNAMO-ELECTRIC MACHINES
    • H02K7/00—Arrangements for handling mechanical energy structurally associated with dynamo-electric machines, e.g. structural association with mechanical driving motors or auxiliary dynamo-electric machines
    • H02K7/18—Structural association of electric generators with mechanical driving motors, e.g. with turbines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Power Engineering (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3218849A 2021-05-14 2022-05-13 Variants of sirt6 for use in preventing and/or treating age-related diseases Pending CA3218849A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163188573P 2021-05-14 2021-05-14
US63/188,573 2021-05-14
PCT/US2022/029213 WO2022241228A2 (en) 2021-05-14 2022-05-13 Variants of sirt6 for use in preventing and/or treating age-related diseases

Publications (1)

Publication Number Publication Date
CA3218849A1 true CA3218849A1 (en) 2022-11-17

Family

ID=84029856

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3218849A Pending CA3218849A1 (en) 2021-05-14 2022-05-13 Variants of sirt6 for use in preventing and/or treating age-related diseases

Country Status (5)

Country Link
US (1) US20240277868A1 (https=)
EP (1) EP4338267A4 (https=)
JP (1) JP2024518665A (https=)
CA (1) CA3218849A1 (https=)
WO (1) WO2022241228A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4630038A1 (en) * 2022-12-08 2025-10-15 Genflow Biosciences Srl Variants of sirtuin 6 for the treatment of non-alcoholic fatty liver disease
EP4665406A1 (en) * 2023-02-14 2025-12-24 The Trustees of Columbia University in the City of New York Crispr-transposon systems and components
WO2026062177A1 (en) 2024-09-20 2026-03-26 Genflow Biosciences Srl Variants of sirtuin 6 for the treatment of muscular diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110113498A1 (en) * 2008-05-15 2011-05-12 Westphal Christoph H Sirt1 polymorphic variants and methods of use thereof
JP2015193582A (ja) * 2014-03-28 2015-11-05 国立大学法人 東京大学 イミダゾールジペプチドを含む剤
WO2017201425A1 (en) * 2016-05-20 2017-11-23 The Trustees Columbia University In The City Of New York Anabolic enhancers for ameliorating neurodegeneration
AU2017378427A1 (en) * 2016-12-14 2019-06-20 Ligandal, Inc. Methods and compositions for nucleic acid and protein payload delivery

Also Published As

Publication number Publication date
US20240277868A1 (en) 2024-08-22
WO2022241228A3 (en) 2023-01-05
EP4338267A2 (en) 2024-03-20
WO2022241228A2 (en) 2022-11-17
JP2024518665A (ja) 2024-05-01
EP4338267A4 (en) 2025-01-08

Similar Documents

Publication Publication Date Title
EP3397261B1 (en) Sub-mitochondrial particles for use in treating cardiovascular diseases
CN110446785B (zh) Hsd17b13变体及其应用
van der Vliet et al. Dual oxidase: a novel therapeutic target in allergic disease
CA3218849A1 (en) Variants of sirt6 for use in preventing and/or treating age-related diseases
Sun et al. Sam68 is required for DNA damage responses via regulating poly (ADP-ribosyl) ation
Novak et al. The adaptor protein Miro1 modulates horizontal transfer of mitochondria in mouse melanoma models
RU2768043C2 (ru) Искусственно созданная система управления функцией шк
CN114127269A (zh) Alt癌症的治疗
Xue et al. Metastasis suppressor NME1 promotes non-homologous end joining of DNA double-strand breaks
Masud et al. Genetic suppression features ABHD18 as a Barth syndrome therapeutic target
Cheng et al. Loss of fragile WWOX gene leads to senescence escape and genome instability
WO2013020366A1 (zh) 乙酰胆碱酯酶作为核酸酶的应用
US11439640B2 (en) Pharmaceutical composition comprising substance inhibiting enzymatic activity of peroxiredoxin 2 as effective ingredient for treatment of colorectal cancer
Chi et al. HDAC6 inhibition upregulates endothelial SOD3 expression via Sp1 acetylation and attenuates angiotensin II‐induced hypertension
JP2016507522A (ja) ミトコンドリア疾患及び神経変性疾患を処置するための方法
Tang et al. Suppression of isoprenylcysteine carboxylmethyltransferase compromises DNA damage repair
Ho et al. Yeast apurinic/apyrimidinic endonuclease Apn1 protects mammalian neuronal cell line from oxidative stress
Freund et al. Nek family members regulate Rad54 during homologous recombination in developing mice
Karbassi et al. Role of a childhood cancer-linked BRIP1/FANCJ germline variant in genomic instability and cancer cell vulnerability
Figlioli et al. Exploring the endonuclease MUS81 as a new factor impacting on cancer chemosensitivity
Xue et al. Knockout and Inhibition of Ape1: Roles of Ape1 in Base Excision DNA Repair and Modulation of Gene Expression. Antioxidants 2022, 11, 1817
Bazzani Role of mitochondrial APE1 in early stages of hepatocellular carcinoma
Ayyildiz Bioinformatics approaches to investigate interactomics data in DNA damage responses and alternative splicing events as new players in Huntington’s Disease
WO2026097104A2 (en) Chimeric protein compositions for cancer therapy and methods of use thereof
Santos The role of HDAC8 in the maintenance of mitotic fidelity

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250505

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250505